These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 10394285)

  • 1. [Pharmacological principles for the treatment of heroin abuse].
    Oye I
    Tidsskr Nor Laegeforen; 1999 May; 119(14):2066-9. PubMed ID: 10394285
    [No Abstract]   [Full Text] [Related]  

  • 2. [Reduced drug craving and better social function with buprenorphine therapy. Combination therapy as an alternative to methadone therapy in heroin addiction].
    Heilig M; Kakko J
    Lakartidningen; 2003 Aug; 100(32-33):2526-7. PubMed ID: 12959012
    [No Abstract]   [Full Text] [Related]  

  • 3. [Buprenorphine as maintenance treatment in rehabilitation of heroin addicts].
    Bramness JG; Bachs LC; Waal H
    Tidsskr Nor Laegeforen; 2002 Oct; 122(25):2452-4. PubMed ID: 12448114
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antagonist-agonist combinations as therapies for heroin addiction: back to the future?
    Nutt DJ
    J Psychopharmacol; 2010 Feb; 24(2):141-5. PubMed ID: 20145102
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Documented effect of methadone, but not naltrexone].
    Heilig M
    Lakartidningen; 2002 Feb; 99(6):551-2. PubMed ID: 11881232
    [No Abstract]   [Full Text] [Related]  

  • 6. [Buprenorphine as a new alternative for detoxification of heroin addicts. It causes only mild withdrawal problems, abating quickly].
    Blennow G; Fergusson A; Medvedeo A
    Lakartidningen; 2000 Apr; 97(15):1830-3. PubMed ID: 10815411
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Methadone and naltrexone in heroin addiction--an explanation from the SBU].
    Asplund K; Jonsson E
    Lakartidningen; 2002 Feb; 99(6):552-3. PubMed ID: 11881233
    [No Abstract]   [Full Text] [Related]  

  • 8. Quality of life among heroin users on buprenorphine versus methadone maintenance.
    Ponizovsky AM; Grinshpoon A
    Am J Drug Alcohol Abuse; 2007; 33(5):631-42. PubMed ID: 17891656
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Overcoming opioid blockade from depot naltrexone (Prodetoxon).
    Kruptisky EM; Burakov AM; Tsoy MV; Egorova VY; Slavina TY; Grinenko AY; Zvartau EE; Woody GE
    Addiction; 2007 Jul; 102(7):1164-5. PubMed ID: 17498182
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Contemporary methods in pharmacotherapy in the opiate dependent treatment.
    Radomska M; Bisaga A; Popik P
    Przegl Lek; 2000; 57(10):509-18. PubMed ID: 11199877
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rapid detoxification from opioid dependence under general anaesthesia versus standard methadone tapering: abstinence rates and withdrawal distress experiences.
    Krabbe PF; Koning JP; Heinen N; Laheij RJ; van Cauter RM; De Jong CA
    Addict Biol; 2003 Sep; 8(3):351-8. PubMed ID: 13129838
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Heroin detoxification with a single high dose of buprenorphine.
    Kutz I; Reznik V
    Isr J Psychiatry Relat Sci; 2002; 39(2):113-9. PubMed ID: 12227226
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Non-injecting routes of administration among entrants to three treatment modalities for heroin dependence.
    Darke S; Hetherington K; Ross J; Lynskey M; Teesson M
    Drug Alcohol Rev; 2004 Jun; 23(2):177-83. PubMed ID: 15370024
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-acting opioid-agonists in the treatment of heroin addiction: why should we call them "substitution"?
    Gerra G; Maremmani I; Capovani B; Somaini L; Berterame S; Tomas-Rossello J; Saenz E; Busse A; Kleber H
    Subst Use Misuse; 2009; 44(5):663-71. PubMed ID: 19360539
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Maintenance treatment with depot opioid antagonists in subcutaneous implants: an alternative in the treatment of opioid dependence.
    Carreño JE; Alvarez CE; Narciso GI; Bascarán MT; Díaz M; Bobes J
    Addict Biol; 2003 Dec; 8(4):429-38. PubMed ID: 14690879
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The acceptability, safety, and tolerability of methadone/naloxone in a 50:1 ratio.
    Bell J; Shearer J; Ryan A; Graham R; Korompay K; Rizzo S; Sindhusake D; Somogyi AA
    Exp Clin Psychopharmacol; 2009 Jun; 17(3):146-53. PubMed ID: 19586229
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical treatment of opioid addiction and dependence.
    Ling W; Rawson RA; Compton M
    Methods Mol Med; 2003; 84():285-95. PubMed ID: 12703332
    [No Abstract]   [Full Text] [Related]  

  • 18. Methadone maintenance: optimizing dosage by estimating plasma level.
    Dole VP
    J Addict Dis; 1994; 13(1):1-4. PubMed ID: 8018735
    [No Abstract]   [Full Text] [Related]  

  • 19. Role of buprenorphine in the management of heroin addiction.
    Sung S; Conry JM
    Ann Pharmacother; 2006 Mar; 40(3):501-5. PubMed ID: 16434562
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Severe opiate withdrawal in a heroin user precipitated by a massive buprenorphine dose.
    Clark NC; Lintzeris N; Muhleisen PJ
    Med J Aust; 2002 Feb; 176(4):166-7. PubMed ID: 11913917
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.